• Publications
  • Influence
Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL.
Epidemiologic data show that the immune system may control or promote the emergence and growth of neoplastic lymphomatous clones. Conversely, systemic lymphomas, especially myeloma and chronicExpand
  • 85
  • 4
  • Open Access
Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
Tumor mutational burden (TMB) represents a new determinant of clinical benefit from immune checkpoint blockade that identifies responders independent of PD‐L1 expression levels and is currently beingExpand
  • 40
  • 3
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial
Background Large-cell neuroendocrine carcinoma of the lung (LCNEC) is a rare disease with poor prognosis and limited treatment options. Neuroendocrine tumors frequently show overactivation of theExpand
  • 26
  • 2
FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
Although targeted therapy has improved the survival rates in the last decade, non-small-cell lung cancer (NSCLC) is still the most common cause of cancer-related death. The challenge of identifyingExpand
  • 8
  • 2
  • Open Access
Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy
Background Systemic inflammation appears to play a role in the progression of numerous solid tumors by promoting tumor proliferation. Our current study aimed to evaluate the role of inflammatoryExpand
  • 12
  • 2
  • Open Access
EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non‐small cell lung cancer
In order to identify anaplastic lymphoma kinase‐driven non‐small cell lung cancer (ALK+ NSCLC) patients with a worse outcome, who might require alternative therapeutic approaches, we retrospectivelyExpand
  • 21
  • 1
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system
Total body irradiation has been the mainstay of conditioning since the inception of allogeneic hematopoietic cell transplantation, but toxicity often precludes its use. For less-fit patients withExpand
  • 8
  • 1
EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC.
Anaplastic lymphoma kinase ( ALK ) gene fusions drive approximately 5% of non-small cell lung cancers (NSCLC) (1). Fluorescence in situ hybridization (FISH) and immunohistochemistry are widely usedExpand
  • 5
  • 1
Optimizing panel-based tumor mutational burden (TMB) measurement.
BACKGROUND Panel-based estimates of Tumor Mutational Burden (psTMB) are increasingly replacing whole-exome-sequencing (WES) Tumor mutational burden as predictive biomarker of immune checkpointExpand
  • 27
  • Open Access
A Novel Thymoma-Associated Immunodeficiency with Increased Naive T Cells and Reduced CD247 Expression
The mechanisms underlying thymoma-associated immunodeficiency are largely unknown, and the significance of increased blood γδ Τ cells often remains elusive. In this study we address these questionsExpand
  • 12